{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:58:09Z","timestamp":1765598289131,"version":"3.48.0"},"reference-count":14,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007299","name":"Harvard Catalyst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002541"],"award-info":[{"award-number":["UL1 TR002541"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007299","name":"The Harvard Clinical and Translational Science Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cutaneous squamous cell carcinoma in situ (SCCis) can be classified histopathologically into four subtypes: full-thickness (FT), hypertrophic actinic keratosis (HAK), Bowenoid, and acantholytic types. 3%\u20135% of SCCis lesions progress to invasive squamous cell carcinoma (iSCC), however progression risk by subtype has not been assessed. Aim one of this study is to quantitatively assess the risk of iSCC associated with each histological subtype of SCCis. Aim two is to evaluate if the histological grade of iSCC differs among subtypes of the associated SCCis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The pathology information system at our institution was queried for cutaneous SCCis cases with and without associated iSCC from 2020 to 2022. The study group consisted of 65 cases of SCCis with associated iSCC and control group 65 randomly selected cases of SCCis without invasion. For each case SCCis subtype was classified as FT, HAK, Bowenoid or acantholytic type. iSCCs were classified as low grade if well to moderately differentiated (LG) and high grade (HG) if moderately to poorly differentiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>iSCC was most often associated with HAK-type SCCis, followed by acantholytic and FT-type SCCis, with Bowenoid type rarely associated with iSCC. 41% (14\/34) of iSCCs associated with HAK-type SCCis were HG compared with 84% (21\/25) for FT-type SCCis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iSCC is most often associated with HAK-type SCCis, followed by acantholytic and FT-types, and rarely with Bowenoid type. HG invasive SCC is most often associated with FT-type, and LG with HAK-type SCCis. Stratifying SCCis by subtype can inform clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2024-209608","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:30:20Z","timestamp":1717547420000},"page":"765-769","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Invasion risk of cutaneous squamous cell carcinoma in situ by histological subtype: a retrospective cohort study"],"prefix":"10.1136","volume":"78","author":[{"given":"Danielle K","family":"Stamer","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Goldsmith","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E","family":"Dodge","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4712-7001","authenticated-orcid":false,"given":"Steven R","family":"Tahan","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"2025121219550888000_78.11.765.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2004.00025.x","article-title":"Squamous cell carcinoma in situ of the skin: history, presentation, biology, and treatment","volume":"45","author":"Arlette","year":"2004","journal-title":"Aust J Dermatology"},{"key":"2025121219550888000_78.11.765.2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/107327480100800409","article-title":"Histologic variants of squamous cell carcinoma of the skin","volume":"8","author":"Rinker","year":"2001","journal-title":"Cancer Control"},{"key":"2025121219550888000_78.11.765.3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/DAD.0000000000000354","article-title":"Histopathologic variants of cutaneous squamous cell carcinoma in situ with analysis of multicentric subtypes: possible relationship to HPV","volume":"37","author":"Gross","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"2025121219550888000_78.11.765.4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1988"},{"key":"2025121219550888000_78.11.765.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70137-3"},{"key":"2025121219550888000_78.11.765.6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-022-00731-x","article-title":"Advances in topical treatments of cutaneous malignancies","volume":"24","author":"Algarin","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025121219550888000_78.11.765.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153653","article-title":"Advances in cutaneous squamous cell carcinoma management","volume":"14","author":"Burns","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025121219550888000_78.11.765.8","doi-asserted-by":"crossref","unstructured":"Masterpol KS , Primiani A , Duncan LM . Progression of Actinic Keratosis to squamous cell carcinoma. In: Atlas of Essential Dermatopathology. London, UK: Springer, 2013: 58\u20139.","DOI":"10.1007\/978-1-4471-4471-7_25"},{"key":"2025121219550888000_78.11.765.9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/DAD.0b013e31820fdc5e","article-title":"Progression from atypical\/dysplastic intraepidermal proliferations and carcinoma in situ to invasive tumors: a pathway based on current knowledge","volume":"33","author":"Chisholm","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"2025121219550888000_78.11.765.10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/bjd.18338","article-title":"The clinical course of actinic keratosis correlates with underlying molecular mechanisms","volume":"182","author":"Bakshi","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025121219550888000_78.11.765.11","doi-asserted-by":"crossref","DOI":"10.3390\/genes11070751","article-title":"Prognostic significance of RAS mutations and P53 expression in cutaneous squamous cell carcinomas","volume":"11","author":"Campos","year":"2020","journal-title":"Genes (Basel)"},{"key":"2025121219550888000_78.11.765.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.07.172"},{"key":"2025121219550888000_78.11.765.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07121.x"},{"key":"2025121219550888000_78.11.765.14","unstructured":"Heppt MV , Schlager G , Berking C , et al . Epithelial precancerous lesions. In: Kang S , Amagai M , Bruckner AL , eds. Fitzpatrick\u2019s Dermatology. 9th edn. McGraw Hill, 2019. Available: https:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=2570\u00a7ionid=210434201"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2024-209608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:55:18Z","timestamp":1765598118000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2024-209608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jcp-2024-209608"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2024-209608","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}